Skip to main content
micro-community-banner
 
  • Saved

made a Post

Efficacy and safety of treatment modalities across EGFR selected/unselected populations with non-small cell lung cancer and brain metastases: A systematic review and Bayesian network meta-analysis - PubMed

Osimertinib appears to be the most effective and safest treatment in NSCLC patients with brain metastases, harboring EGFR positive mutations. The anti-PD1 monoclonal antibody and conventional chemotherapy combination increases survival ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34126551/

  • Saved

made a Post

Prediction of lymph nodes micrometastasis in NSCLC - CMAR | CMAR

Globally, lung cancer cases and deaths remain rising over the past decade. In 2018, the Global Cancer Observatory Organization (GLOBOCAN) estimated more than 2 million new cases and 1.76 million ..... see more

Source : https://www.dovepress.com/machine-learning-for-the-prediction-of-lymph-nodes-micrometastasis-in--peer-reviewed-fulltext-article-CMAR

  • Saved

made a Post

Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells

Macrophages have a key role in shaping the tumour microenvironment (TME), tumour immunity and response to immunotherapy, which makes them an important target for cancer treatment1,2. However, modulating macrophages has ..... see more

Source : https://www.nature.com/articles/s41586-021-03651-8

  • Saved

made a Post

Digital PCR detection of EGFR somatic mutations in non-small-cell lung cancer formalin fixed paraffin embedded samples - PubMed

doi: 10.1016/j.mcp.2021.101745. Online ahead of print. 1 Laboratório de Genética Molecular Humana, Universidade Federal Do Paraná, Curitiba, Brazil. 2 Laboratório de Genética Molecular Humana, Universidade Federal Do Paraná, Curitiba, Brazil; ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34089806/

  • Saved

made a Post

EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer - PubMed

Although phenotypically similar to patients with common EGFR mutations, patients with EGFR ex20-mut had worse survival, perhaps due to the lack of targeted therapies. Chemotherapy was superior to conventional EGFR ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34127383/

  • Saved

Commented on 's Post

Circulating biomarkers for monitoring therapy response and detection of disease progression in lung cancer patients - PubMed

Liquid biopsies have become of interest as minimally invasive ways to monitor treatment response in lung cancer patients. Circulating tumor DNA (ctDNA) and protein biomarkers are evaluated for their added ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34107412/

Show More Comments

  • 1 week
    Key Points • In the current prospective study, researchers assessed a sample of 40 patients in which one driver mutation in ctDNA (EGFR, KRAS or BRAF) was detected, with a minimum Show More
  • Saved

Commented on 's Post

Can 18 F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer? A systematic review and meta-analysis - PubMed

1 Department of Nuclear Medicine, The First Hospital of China Medical University, Shenyang, China. 2 Department of Nuclear Medicine, The First Hospital of China Medical University, Shenyang, China ymli2001@163.com. Free ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34103313/

Show More Comments

  • 1 week
    Key Points • Some research has suggested that a higher uptake of 18F-FDG is predictive of mutant EGFR in the context of NSCLC. Overall, however, findings on the topic are mixed, Show More
  • Saved

made a Post

Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy - PubMed

doi: 10.3171/2020.10.JNS201787. Online ahead of print. 1 Departments of1Neurosurgery and. 2 2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland. 3 3Radiation Oncology, Johns Hopkins University School of Medicine; ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34087798/

  • Saved

made a Post

CD151 drives cancer progression depending on integrin α3β1 through EGFR signaling in non-small cell lung cancer - PubMed

doi: 10.1186/s13046-021-01998-4. 1 Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Soochow University, Suzhou, 215006, China. 2 Institute of Respiratory Diseases, Soochow University, 215006, Suzhou, China. ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34108040/

  • Saved

made a Post

Molecular Identification and Genetic Characterization of Early-Stage Multiple Primary Lung Cancer by Large-Panel Next-Generation Sequencing Analysis

ObjectiveThe incidence of early stage multiple primary lung cancer (MPLC) has been increasing in recent years, while the ideal strategy for its diagnosis and treatment remains controversial. see more

Source : https://www.frontiersin.org/articles/10.3389/fonc.2021.653988/full

  • Saved

Treatment strategies in EGFR-mutated NSCLC

Our latest Featured Discussion focused on Treatment Strategies in EGFR-Mutated NSCLC. Members from Lung Cancer Connect participated in peer-to-peer discussion regarding their concerns and interests on the topic. Below is a summary of highlights from the conversation:

  • Your peers indicate that osimertinib is their preferred first-line therapy for NSCLC patients with sensitizing EGFR mutations as osimertinib has been the first-line standard-of-care therapy since its approval in April 2018.
  • Although fellow members mention that they would consider the combination of EGFR TKI and VEGF therapy as an option through clinical trials, awareness around the recent approval for the combination of first-generation EGFR TKI erlotinib and VEGFR2 inhibitor ramucirumab remains low.
  • Comments from your peers:
    • “Osimertinib is typically first line, unless there are hurdles (insurance, patient access) or toxicity concerns (diarrhea, cytopenias, etc)”
    • “Other combination agents may have additional clinical benefits, such as TKI and VEGF, with or without chemotherapy.”
    • “Investigational studies are looking at the addition of VEGF directed therapy to the TKI as well the addition of chemotherapy to the TKI”
    • “Clinical trials with TKI in combination with IO or chemo should also be considered if available and patient is willing for a clinical trial.”

  • Saved

Commented on 's Post

Analysis of Delayed Surgical Treatment and Oncologic Outcomes in Clinical Stage I Non-Small Cell Lung Cancer - PubMed

Using a more precise definition for TTS, this study found that surgical procedures delayed more than 12 weeks were associated with increased risk of recurrence and worse survival. These findings ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34042991/

Show More Comments

  • 1 week 6 days
    Key Points • In the current retrospective study, researchers employed a uniform method to assess surgical treatment delay and its associated outcomes in 9904 patients who underwent surgical treatment for clinical Show More
  • Saved

Commented on 's Post

Multi-channel multi-task deep learning for predicting EGFR and KRAS mutations of non-small cell lung cancer on CT images - PubMed

1 School of Software, Taiyuan University of Technology, Taiyuan, China. 2 School of Information and Computer, Taiyuan University of Technology, Taiyuan, China. 3 Department of Radiology, Shanxi Province Cancer Hospital, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34079707/

Show More Comments

  • 1 week 6 days
    Key Points • As a means to provide targeted therapy, the prediction of the mutation status of EGFR and KRAS in NSCLC is useful. After all, CT is cost-effective and non-invasive. Show More

Can we improve RET-positive NSCLC patient outcomes?

Our latest Featured Discussion focused on whether or not we can improve RET-positive NSCLC patient outcomes. Members from Lung Cancer Connect participated in peer-to-peer discussion regarding their concerns and interests on the topic. Below is a summary of highlights from the conversation:

  • All members noted that they already test for RET rearrangements and incorporate the results into their prescribing decisions, with some mentioning that testing for RET rearrangements is included in standard next-generation sequencing (NGS) panels. 
  • Many of your peers indicated that they plan to use targeted therapies, specifically RET inhibitors, to treat patients who test positive for RET rearrangements. 
  • One member stated, “I routinely include RET rearrangements in NSCLC biomarker tests, and if a patient tests positive, this may impact therapy” 
  • In general, most members prefer to use RET inhibitors instead of chemo-immunotherapy in the first-line setting for patients with RET rearrangements. However, another member notes that they prefer to use selpercatinib or pralsetinib in the second-line setting for patients who have relapsed after first-line treatment with chemo-immunotherapy.  Other comments included:
    • “Having a targeted therapy, such as RET TKIs, is an advantage and should be utilized when feasible.”
    • “I have used both agents and have more experience with selpercatinib in terms of safety profile.”
    • “I prefer a RET inhibitor over chemo-immunotherapy in first line.”
    • “I will start all RET mutated pts on targeted drugs in first line.”
    • “[RET rearrangements] can be targeted using one of the approved TKI’s in patients who relapse after chemo-immunotherapy.”

 

  • Saved

made a Post

Polymorphisms in EGFR Gene Predict Clinical Outcome in Unresectable Non-Small Cell Lung Cancer Treated with Radiotherapy and Platinum-Based Chemoradiotherapy - PubMed

For non-small cell lung cancer (NSCLC), radiotherapy (RT) and platinum-based chemotherapy (CHT) are among the main treatment options. On the other hand, radioresistance and cytotoxic drug resistance are common causes ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34070597/

  • Saved

made a Post

Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer - PubMed

1 Department of Biochemistry, Molecular and Cellular Biology, Stony Brook University, Stony Brook, NY 11794, USA. 2 Stony Brook Cancer Center, Stony Brook University Hospital, Stony Brook, NY 11794, USA. ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34073823/

  • Saved

made a Post

CRKL is a critical target of Hh-GLI2 pathway in lung adenocarcinoma - PubMed

Lung adenocarcinoma (LUAD) is one of the important components of non-small-cell lung cancer (NSCLC) and leads to many deaths every year. During the initiation and progression of the LUAD, the ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34076957/

  • Saved

Commented on 's Post

Malayoside, a Cardenolide Glycoside Extracted from Antiaris Toxicaria Lesch, Induces Apoptosis in Human Non-small Lung Cancer Cells via MAPK-Nur77 Signaling Pathway - PubMed

Lung cancer is the leading cause of cancer deaths in the world. Non-small cell lung cancer (NSCLC), with poor prognosis and resistance to chemoradiotherapy, is the most common histological type ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34043967/

Show More Comments

  • 2 weeks 5 days
    Key Points • In the current study involving cell line, researchers demonstrated that the apoptotic effect of malayoside resulted from the induction of Nur77 expression, cytoplasmic localization, and mitochondrial targeting. • Nur77 Show More